1

1 Cholera deaths during outbreaks in Uvira, eastern Democratic

2 Republic of the Congo, 10-35 months after mass vaccination

- 3 Patrick Musole Bugeme^{1,2}, Hanmeng Xu¹, Chloe Hutchins³, Juan Dent Hulse¹, Jaime Mufitini Saidi⁴,
- 4 Baron Bashige Rumedeka^{1,4}, Moïse Itongwa¹, Joël Faraja Zigashane Mashauri¹, Faraja Masembe
- 5 Lulela¹, Justin Bengehya⁵, Jean-Claude Kulondwa⁵, Amanda K Debes⁶, Iza Ciglenecki⁷, Esperance
- 6 Tshiwedi⁸, Faida Kitoga⁸, Tavia Bodisa-Matamu⁸, Taty Nadège⁹, Hugo Kavunga-Membo^{8,10}, Octavie
- 7 Lunguya¹⁰, Placide Okitayemba Welo⁹, Jackie Knee³, Daniel Mukadi-Bamuleka^{8,10}, Andrew S.
- 8 Azman^{1,11,12*}, Espoir Bwenge Malembaka^{1,2}
- 9
- ¹Department of Epidemiology, Johns Hopkins University, Baltimore, MD 21205, USA
- ¹¹ ²Centre for Tropical Diseases and Global Health (CTDGH), Université Catholique de Bukavu,
- 12 Bukavu, Democratic Republic of the Congo
- ³Department of Disease Control, London School of Hygiene & Tropical Medicine, UK
- ⁴*Ministère de la Santé Publique, Division Provinciale de la Santé Publique du Sud-Kivu, Zone de*
- 15 Santé d'Uvira, Democratic Republic of the Congo
- ⁴*Ministère de la Santé Publique, Zone de Santé d'Uvira, Democratic Republic of Congo*
- ⁵*Ministère de la Santé Publique, Division Provinciale de la Santé Publique du Sud-Kivu, Democratic*
- 18 Republic of the Congo
- ⁶Department of International Health, Johns Hopkins University, Baltimore, MD 21205, USA
- 20 ⁷Médecins Sans Frontières, 1202 Geneva, Switzerland
- 21 ⁸Rodolphe Merieux INRB-Goma Laboratory, Goma, North-Kivu, Democratic Republic of the Congo
- 22 ⁹Programme National d'Elimination de Choléra et lutte contre les autres Maladies 19 Diarrhéiques
- 23 (PNECHOL-MD), Kinshasa, Democratic Republic of the Congo
- 24 ¹⁰Institut National de Recherche Biomédicale, INRB, Kinshasa, Democratic Republic of the Congo
- 25 ¹¹Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals (HUG),, Geneva,
- 26 Switzerland
- 27 ¹²Division of Tropical and Humanitarian Medicine, Geneva University Hospitals (HUG), Geneva,
- 28 Switzerland
- 29
- 30 *Corresponding author:
- 31 Andrew S. Azman (azman@jhu.edu)
- 32
- 33 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health,
- 34 Johns Hopkins University, Baltimore, MD 21205, USA
- 35 Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals (HUG),, Geneva,
- 36 Switzerland
- 37 Division of Tropical and Humanitarian Medicine, Geneva University Hospitals (HUG),
- 38 Geneva, Switzerland
- 39
- 40 Target journal: Open Forum Infectious Diseases:
- 41 <u>https://academic.oup.com/ofid/pages/Submission_Online?login=true</u>
- 42

43 Abstract

- 44 Our understanding of the burden and drivers of cholera mortality is hampered by limited
- 45 surveillance and confirmation capacity. Leveraging enhanced clinical and laboratory
- 46 surveillance in the cholera-endemic community of Uvira, eastern Democratic Republic of
- 47 Congo, we describe cholera deaths across three epidemics between September 2021-
- 48 September 2023, following mass vaccination.

3

61	Cholera is an acute diarrheal disease that can rapidly cause severe dehydration and death
62	without prompt and aggressive rehydration[1]. Estimates of the true burden of cholera are
63	highly uncertain because surveillance systems often lack routine identification and testing of
64	suspected cases, and documentation of community cases and deaths is limited. In resource-
65	constrained settings, passive, facility-based surveillance data on mortality are likely to
66	underestimate true mortality; contributing factors include limited patient access to health
67	facilities and incentives for under-reporting[2-5]. Additionally, limited access to
68	confirmatory laboratories for cases and deaths may lead to distorted estimates of the true
69	cholera mortality, both at local and global levels[6]. In the city of Uvira in South Kivu
70	[eastern Democratic Republic of the Congo (DRC)], we implemented an enhanced cholera
71	surveillance system as part of an impact evaluation of preventive mass oral cholera
72	vaccination campaigns conducted in 2020. The killed oral cholera vaccine (kOCV) Euvichol-
73	plus was administered to individuals ≥ 12 months old living in Uvira in two mass campaigns
74	conducted in July-August and October 2020. Here, we describe cholera deaths across three
75	cholera epidemics in the first three years after vaccination (Figure).

76 Methods

77 Between September 1, 2021 – September 30, 2023 (10-35 months after the second round of 78 vaccination), suspected cholera cases were recruited at the two cholera treatment facilities in 79 Uvira: the Cholera Treatment Centre at the Uvira General Referral Hospital; and Cholera 80 Treatment Unit at the Kalundu CEPAC health center (both designated as CTC herein). A 81 suspected cholera case was any person ≥ 12 months old, reporting ≥ 3 acute, watery, and non-82 bloody diarrheal stools within the 24 hours before hospitalization. Data on sociodemographic 83 characteristics, clinical manifestations, including the level of dehydration based on the Global 84 Task Force on Cholera Control (GTFCC) guidance, [7] vaccination status, and clinical

4

85	outcome were collected using a structured electronic questionnaire. Written consent was
86	obtained from participants. Rectal swabs and stool samples were collected from consenting
87	patients. Rectal swabs were enriched for 6-18 hours in alkaline peptone water at ambient
88	temperature (~30°C). Crystal VC Rapid Diagnostic Tests (RDTs; Arkay, India) were used to
89	test raw stool samples and rectal swab enrichments. Samples collected after September 2022
90	were cultured at the CTC laboratory, whereas those collected before were tested at Rodolphe
91	Mérieux INRB-Goma laboratory in North Kivu. In addition, stool samples from the 2021-
92	2022 outbreak were spotted onto Whatman 903 Protein Saver Cards (Cytiva, UK) and tested
93	by PCR at Johns Hopkins University[8].
94	Community deaths were not systematically captured by the surveillance system, so the study
95	team learned of suspected community cholera deaths through informal means (Appendix).
96	Visits were organized to collect additional information on the circumstances of death, socio-
97	demographics, clinical manifestations, and vaccination status for each suspected community
98	cholera death. Cholera was the suspected cause of death if the deceased was ≥ 12 months old
99	
22	and their family members reported that they experienced acute watery diarrhea in the 24
100	and their family members reported that they experienced acute watery diarrhea in the 24 hours preceding the death, with no other cause of death reported. Biological samples were
100	hours preceding the death, with no other cause of death reported. Biological samples were

103 Pearson's Chi-squared (or Fisher's exact) tests. We estimated the effectiveness of at least one

104 dose of kOCV against severe cholera (defined by a culture/PCR-confirmed cholera case with


105 severe or treatment plan C dehydration) and suspected cholera death (i.e., any suspected

- 106 cholera case dying within the CTC with no other cause of death identified) using the
- 107 screening method, which relies on contrasts of the proportion of cases vaccinated and the
- 108 vaccine coverage in the population[9]. As vaccine coverage declined over time due to

5

- 109 population movement, we estimated a weighted vaccination coverage, based on a log-linear
- 110 regression of data from three representative vaccine coverage surveys conducted 11, 19 and
- 111 29 months after vaccination. We estimated confidence intervals for VE based on a logistic
- 112 regression model, as previously proposed[9].

113 **Results**



114 115

Figure. Weekly cholera incidence (top) and death (bottom) by culture or PCR confirmation results in 116 Uvira, 01 September 2021 to 30 September 2023. Before September 10, 2022, culture was performed with a 117 significant lag at an external reference laboratory (INRB Goma) from wet filter papers (stool or rectal swab 118 enrichments suspended in saline), likely leading to reduced sensitivity for detection of V. cholerae O1. From 119 September 10, 2022, culture has been performed on-site in Uvira. Rapid diagnostic tests (a mix of O1 and 120 O1/O139 tests) were also used throughout the study. For this reason, we show enriched rapid test positive 121 results as dots to help understand which deaths have more laboratory data supporting V. cholerae O1 as the 122 causative agent. Community deaths are highlighted with black boxes. 123

124 During the 25-month study period, 2209 suspected cholera cases were admitted to the CTCs,

- 126 culture or PCR (Table 1). In the same period, 24 suspected cholera deaths were reported, of
- 127 which 18 (75%) occurred within CTCs, with a facility-based suspected case fatality ratio
- 128 (CFR) of 0.81% (18/2209).

¹²⁵ of which 1,312 (61.9%) were RDT-positive and 1,460 (67.3%) cases were confirmed by

6

129 Table 1. Characteristics of patients with cholera who died and survived in the cholera

130 treatment facilities, Uvira, September 2021 to September 2023

Characteristic	Overall,	Suspected cholera deaths, N = 18	Suspected cholera cases (survivors),	P value	
	N = 2,209	- 10	N = 2,191		
Age (years), median (IQR)	17.0 (7.0, 34.0)	40.0 (21.0, 67.8)	17.0 (7.0, 34.0)	< 0.001	
Age group (years)	,	,		< 0.001	
< 5 years	384 (17.4%)	1 (5.6%)	383 (17.5%)		
5-14 years	608 (27.5%)	1 (5.6%)	607 (27.7%)		
15-59 years	1,024 (46.4%)	8 (44.4%)	1,016 (46.4%)		
\geq 60 years	193 (8.7%)	8 (44.4%)	185 (8.4%)		
Sex				0.873	
Female	1,063 (48.1%)	9 (50.0%)	1,054 (48.1%)		
Male	1,146 (51.9%)	9 (50.0%)	1,137 (51.9%)		
Health facility				0.758	
CTC (Uvira Referral Hospital)	1,806 (81.8%)	16 (88.9%)	1,790 (81.7%)		
CTU (Kalundu CEPAC health center)	403 (18.2%)	2 (11.1%)	401 (18.3%)		
Level of dehydration on admission*				0.002	
Mild to moderate	1,060 (48.0%)	2 (11.1%)	1,058 (48.3%)		
Severe	1,149 (52.0%)	16 (88.9%)	1,133 (51.7%)		
Time from symptoms onset to hospitalization				0.253	
< 1 day	1,209 (54.9%)	9 (50.0%)	1,200 (54.9%)		
1 day	776 (35.2%)	9 (50.0%)	767 (35.1%)		
≥ 2 days	219 (9.9%)	0 (0.0%)	219 (10.0%)		
Missing	5	0	5		
Duration of hospitalization				< 0.001	
< 1 day	130 (6.0%)	7 (38.9%)	123 (5.7%)		
1 day	542 (24.8%)	6 (33.3%)	536 (24.7%)		
\geq 2 days	1,512 (69.2%)	5 (27.8%)	1,507 (69.6%)		
Missing	25	0	25		
Comorbidities**				0.490	
No	1,449 (91.9%)	7 (87.5%)	1,442 (92.0%)		
Yes	127 (8.1%)	1 (12.5%)	126 (8.0%)		
Missing	633	10	623		
Sought care at another health facility				0.746	
No	1,875 (84.9%)	15 (83.3%)	1,860 (84.9%)		
Yes	334 (15.1%)	3 (16.7%)	331 (15.1%)		
Treated at home or pharmacy	1			0.557	
No	1,075 (48.7%)	10 (55.6%)	1,065 (48.6%)		
Yes	1,134 (51.3%)	8 (44.4%)	1,126 (51.4%)		

7

Use of antibiotics before admission				0.232
No	1,163 (52.6%)	12 (66.7%)	1,151 (52.5%)	
Yes	1,046 (47.4%)	6 (33.3%)	1,040 (47.5%)	
APW-enriched RDT				0.081
Negative	807 (38.1%)	3 (17.6%)	804 (38.2%)	
Positive	1,312 (61.9%)	14 (82.4%)	1,298 (61.8%)	
Missing	90	1	89	
Culture/PCR confirmed cholera				0.818
Negative	709 (32.7%)	6 (35.3%)	703 (32.7%)	
Positive	1,460 (67.3%)	11 (64.7%)	1,449 (67.3%)	
Missing	40	1	39	
Vaccination status				>0.999***
Not vaccinated	1,688 (81.0%)	11 (84.6%)	1,677 (80.9%)	
At least 1 dose	397 (19.0%)	2 (15.4%)	395 (19.1%)	
Missing	124	5	129	

131 Data are n (proportion) unless otherwise specified. *: The level of dehydration assessed using the Global Task

132 Force on Cholera Control (GTFCC) guidance.[7] **: Comorbidities refer to self-reported diabetes, hypertension,

133 or HIV infection (Appendix). P values are derived from Pearson's Chi-squared test or Fisher's exact test

134 comparing attributes between survivors and those who died, denoted by ***. A confirmed cholera case was

defined by a positive PCR or culture result. A negative case was confirmed by negative PCR and culture, or by a

136 negative culture only result when PCR was not done.

137 Fourteen (82.4%) of the 17 health facility deaths in which a sample was collected tested

138 positive for cholera by RDT, and 11 (64.7%) by culture or PCR. The overall culture/PCR-

139 confirmed facility-based CFR was 11/1449 (0.75%), though this was significantly higher in

140 participants aged \geq 60 years [4.46% (5/107), p=0.010] compared to younger ones. The

suspected cholera CFR in this age-group (≥ 60 years) was 5.45% (11/191) (Table S2).

142 Comparison between suspected cholera deaths and survivors in health facilities revealed that

143 those dying from cholera tended to be older, with a median (interquartile range, IQR) age:

144 40.0 (21.0 - 67.8) years] more than double that of survivors [median (IQR): 17.0 (7.0-34.0)

145 years; p < 0.001], with no difference by sex (Table 1). Suspected cases who died were more

146 likely to have been admitted with severe dehydration compared to survivors (88.9% vs

147 51.7%, p=0.002). Eleven (61.1%) health facility deaths occurred after at least one day of

8

148	hospitalization. Two of the facility deaths with known vaccination status (n=13), both
149	culture-positive, were reported to have received one dose of oral cholera vaccine during the
150	2020 vaccination campaign, but we were unable to confirm these with vaccination cards.
151	The estimated VE was 78.4% (95% CI 74.2-82.4%) against severe culture/PCR-confirmed
152	cholera (dehydration plan C) and 85.5% (95% CI 49.0-97.7%) against death from all-cause
153	diarrhea (suspected cholera death). The method we used to estimate vaccine effectiveness
154	relies heavily on assumptions about the vaccine coverage in the community, and even when
155	assuming a 10% lower vaccination coverage in the population than measured from cross-
156	sectional surveys, the estimated VE against suspected cholera death remained substantial
157	(above 70%) (Figure S1).
158	The age of community deaths ranged between 4-74 years (median: 38 years), with half (n=3)

159 of them being female. Two community deaths had a stool specimen collected and tested

160 positive for cholera by RDT and culture.

161 **Discussion**

162 The 0.81% facility-based CFR for suspected cholera cases observed from this passive 163 surveillance system aligns with the WHO target of <1% and was lower than that reported 164 between 2008-2017 in DRC hotspot health zones (1.1%)[10]. While we captured some 165 community deaths, the true cholera mortality burden in Uvira is likely higher than reported 166 here due to lack of robust community-based surveillance and the number of private health 167 facilities that are not integrated into the official surveillance system. The limited existing 168 studies comparing the reported number of facility deaths to those occurring in both facilities 169 and the community suggest this gap is large [2-4,11]. A study from rural Kenya showed that 170 while suspected cholera cases were under-reported by 37%, suspected cholera deaths were

9

171	under-reported by 200%, implying a 52% underestimate of the community CFR[2-4,11]. In
172	Cameroon, 44% of suspected cholera deaths occurred in the community or during transit to a
173	treatment unit [3]. During the 2010-2011 cholera outbreak in Haiti, community surveys led to
174	almost a 3-fold higher death toll in certain areas compared to official facility-based
175	estimates[4].
176	A previous report from across DRC suggested that 20.8% of the suspected cholera deaths
170	A previous report from across DRC suggested that 20.8% of the suspected choiera deaths
177	during the 2008-2017 period were among those under five years old, a stark contrast to the
178	6.6% in our study [10]. This difference may be a result of several factors including the
179	systematic application of case definitions in Uvira (i.e., improved specificity), differences in
180	health seeking behaviors and/or in the quality of care given to young patients in Uvira.
181	Almost half of the health facility deaths (8/18) occurred among patients aged at least 60
182	years, leading to an unacceptably high age group-specific CFR (4.02%). Moreover, 61.1% of
183	deaths happened after ≥ 1 day of hospitalization. This may be because clinical assessment and
184	management of severe dehydration is challenging in the elderly who might have
185	comorbidities requiring slower rehydration pace to avoid fluid overload. Complications
186	related to underlying comorbidities like cardiovascular diseases, diabetes mellitus, anemia, or
187	malnutrition may be overlooked in cholera treatment centers, particularly in the middle of an
188	outbreak, as rehydration is the priority. CTCs in most humanitarian settings, including in our
189	study site, are not sufficiently equipped for an adequate assessment and management of other
190	health conditions cholera patients may present with, including chronic morbidities. Ensuring
191	that CTCs offer comprehensive and person-centered care (as opposed to solely dehydration-
192	centered care) might contribute to the reduction of cholera CFR, particularly among the
193	elderly.

10

194	Our findings indicate that the only kOCV currently available in the global stockpile
195	(Euvichol-plus) is highly protective against severe cholera and death. The few available
196	studies reporting kOCV effectiveness against severe cholera point to similar levels of
197	protection, ranging from 73% (23 to 91) 4-24 months post-vaccination in Haiti[12] to 48%
198	(16 to 67) in the fourth year post-vaccination in Bangladesh.[13] Despite the relatively small
199	number of deaths limiting more stratified analyses, this study provides the first, insights into
200	kOCV effectiveness against death and suggests that large-scale deployment of kOCVs in
201	preventive vaccination campaigns may substantially contribute to achieving the Global Task
202	Force on Cholera Control's goal of reducing cholera mortality by 90% by 2030.[14]

203 Conclusion

- 204 While the public health community strives to improve the cholera surveillance [15],
- 205 describing the magnitude and drivers of community and confirmed facility deaths is critical
- to help correctly target those most at risk and improve patient care and estimates of cholera
- 207 burden. This study provides a unique insight into confirmed cholera mortality in a resource-
- 208 constrained and endemic setting. Studies with larger sample sizes, including community
- surveillance and in different endemicity settings are needed to confirm our findings.
- 210 Financial support
- This work was supported by the Wellcome Trust and Gavi (GAVI-RFP-2019-062). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

215

211

216 **Potential conflicts of interest**

217

11

218 All other authors report no potential conflicts.

219 **References**

- 1. Kanungo S, Azman AS, Ramamurthy T, Deen J, Dutta S. Cholera. Lancet 2022; 399:1429–1440.
- Shikanga O-T, Mutonga D, Abade M, et al. High mortality in a cholera outbreak in western Kenya after post-election violence in 2008. Am J Trop Med Hyg 2009; 81:1085–1090.
- Djouma FN, Ateudjieu J, Ram M, Debes AK, Sack DA. Factors Associated with Fatal Outcomes
 Following Cholera-Like Syndrome in Far North Region of Cameroon: A Community-Based
 Survey. Am J Trop Med Hyg 2016; 95:1287–1291.
- Luquero FJ, Rondy M, Boncy J, et al. Mortality Rates during Cholera Epidemic, Haiti, 2010-2011. Emerg Infect Dis 2016; 22:410–416.
- Azman AS, Moore SM, Lessler J. Surveillance and the global fight against cholera: Setting priorities and tracking progress. Vaccine 2020; 38 Suppl 1:A28–A30.
- World Health Organization. Weekly epidemiological record. World Health Organization, 22
 SEPTEMBER 2023, 98 YEAR. Available at: http://www.who.int/wer. Accessed 17 October
 2023.
- Global Task Force on Cholera Control (Surveillance Working Group). Interim guidance document on cholera surveillance. GTFCC, 2017. Available at: https://www.gtfcc.org/wpcontent/uploads/2019/10/gtfcc-interim-guidance-document-on-cholera-surveillance.pdf.
 Accessed 3 August 2023.
- Debes AK, Ateudjieu J, Guenou E, et al. Clinical and Environmental Surveillance for Vibrio
 cholerae in Resource Constrained Areas: Application During a 1-Year Surveillance in the Far
 North Region of Cameroon. Am J Trop Med Hyg **2016**; 94:537–543.
- Farrington CP. Estimation of vaccine effectiveness using the screening method. Int J Epidemiol 1993; 22:742–746.
- Ingelbeen B, Hendrickx D, Miwanda B, et al. Recurrent Cholera Outbreaks, Democratic
 Republic of the Congo, 2008-2017. Emerg Infect Dis 2019; 25:856–864.
- Pampaka D, Ciglenecki Z, Alberti K, Olson D. Risk factors of cholera mortality: a scoping
 review. Global Task Force on Cholera Control (GTFCC) , 2022. Available at:
 https://www.gtfcc.org/wp-content/uploads/2023/02/gtfcc-risk-factors-of-cholera-mortality.pdf.
 Accessed 14 March 2023.
- 12. Ivers LC, Hilaire IJ, Teng JE, et al. Effectiveness of reactive oral cholera vaccination in rural
 Haiti: a case-control study and bias-indicator analysis. The Lancet Global Health 2015; 3:e162–
 e168.
- Ali M, Qadri F, Kim DR, et al. Effectiveness of a killed whole-cell oral cholera vaccine in
 Bangladesh: further follow-up of a cluster-randomised trial. Lancet Infect Dis 2021; 21:1407–
 1414.
- World Health Organization. Global Task Force on Cholera Control. Ending Cholera, a Global
 Roadmap to 2030. World Health Organization, 2017.

12

256	15.	GTFCC. Public health	surveillance for	cholera:	Interim g	uidance.	Global	Taskforce of	n Cholera
-----	-----	----------------------	------------------	----------	-----------	----------	--------	--------------	-----------

- 256 257 258 Control (GTFCC), 2023. Available at: https://www.gtfcc.org/wp-content/uploads/2023/02/gtfcc-public-health-surveillance-for-cholera-interim-guidance.pdf. Accessed 14 March 2023.

259